Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Alkermes) ALK4230-A101A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsHirte, Dr HalOpen to recruitmentNCT02799095
(BI) 1381.1 / REFMAL 473An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours Hirte, Dr HalOpen to recruitmentNCT02952248
(BMS) CA021002A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid TumorsHotte, Dr SebastienOpen to recruitmentNCT03251924
(BMS) CA209848 / CheckMate 848A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or
Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High
Tumor Mutational Burden (TMB-H)
Hotte, Dr SebastienOpen to recruitmentNCT03668119
(CCTG) IND.228A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare TumoursHirte, Dr HalOpen to recruitmentNCT02879162
(Esperas) ESPS-001A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic CancerHirte, Dr HalOpen to recruitmentNCT02632448
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynOpen to recruitmentNCT03746431
Download PDF